| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the University of Lübeck, Lübeck, Germany.
PURPOSE. To evaluate the effect of photodynamic therapy (PDT) on perfusion and vascular integrity of choroidal neovascularization (CNV) and collateral physiological choroid.
METHODS. In a prospective clinical trial, patients with subfoveal CNV were treated with PDT and verteporfin. Indocyanine green angiography (ICG-A), using a confocal laser scanning system with tomographic sections, was performed continuously 1 week before and 1, 4, and 12 weeks after and a mean long-term follow-up of 16.5 months after the final PDT. Vascular changes were localized tomographically and quantified on the level of the CNV and collateral choroid according to early lesion size, late hyperfluorescence, and persistence or recurrence. Data were analyzed separately from 38 eyes in a single- and 12 eyes in a multiple-treatment regimen.
RESULTS. CNV lesions were significantly reduced in size and late hyperfluorescence. However, 54% of lesions primarily demonstrated persistence, typically of the choroidal feeding complex, which was only detectable by ICG-A. Regrowth from the feeding vessel occurred regularly, but did not reach baseline dimensions. Collateral choroid exposed to photoactivation exhibited choriocapillary occlusion. Progressive recanalization was documented within 4 to 12 weeks after both single and multiple PDT. Residual changes in the choroidal filling pattern often persisted during long-term follow-up.
CONCLUSIONS. Tomographic ICG-A after PDT reveals persistence of CNV and/or the feeder vessel and a reduction in perfusion within the entire photosensitized area, including the surrounding choroid. Repair mechanisms occur slowly in neovascular and normal choroidal structures.
This article has been cited by other articles:
|
|
 |
|
  S Sacu, A Varga, S Michels, G Weigert, K Polak, P V Vecsei-Marlovits, and U Schmidt-Erfurth Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study Br. J. Ophthalmol., October 1, 2008; 92(10): 1347 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Parmeggiani, C. Costagliola, D. Gemmati, S. D'Angelo, P. Perri, C. Campa, L. Catozzi, F. Federici, A. Sebastiani, and C. Incorvaia Coagulation Gene Predictors of Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3100 - 3106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tatar, K. Shinoda, E. Kaiserling, G. Pertile, C. Eckardt, A. Mohr, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, and S. Grisanti Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal Neovascularization Arch Ophthalmol, February 1, 2008; 126(2): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ishikawa, M. Kondo, Y. Ito, M. Kikuchi, H. Nishihara, C.-H. Piao, T. Sugita, and H. Terasaki Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2254 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Kozak, L Cheng, D E Cochran, and W R Freeman Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration Br. J. Ophthalmol., September 1, 2006; 90(9): 1152 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Petermeier, O Tatar, W Inhoffen, M Volker, B A Lafaut, S Henke-Fahle, F Gelisken, F Ziemssen, S Bopp, K U Bartz-Schmidt, et al. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes Br. J. Ophthalmol., August 1, 2006; 90(8): 1034 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tatar, E. Kaiserling, A. Adam, F. Gelisken, K. Shinoda, M. Volker, B. A. Lafaut, K. U. Bartz-Schmidt, and S. Grisanti Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol, June 1, 2006; 124(6): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Garcia-Layana, A Salinas-Alaman, M J Maldonado, C Sainz-Gomez, and A Fernandez-Hortelano Optical coherence tomography to monitor photodynamic therapy in pathological myopia Br. J. Ophthalmol., May 1, 2006; 90(5): 555 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sarks, K Tang, M Killingsworth, J Arnold, and S Sarks Development of atrophy of the retinal pigment epithelium around disciform scars. Br. J. Ophthalmol., April 1, 2006; 90(4): 442 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Michels, F. Hansmann, W. Geitzenauer, and U. Schmidt-Erfurth Influence of Treatment Parameters on Selectivity of Verteporfin Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tzekov, T. Lin, K.-M. Zhang, B. Jackson, A. Oyejide, W. Orilla, A. D. Kulkarni, B. D. Kuppermann, L. Wheeler, and J. Burke Ocular Changes after Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Krebs, S Binder, U Stolba, K Schmid, C Glittenberg, W Brannath, and A Goll Optical coherence tomography guided retreatment of photodynamic therapy Br. J. Ophthalmol., September 1, 2005; 89(9): 1184 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Klais, M. D. Ober, K. B. Freund, L. H. Ginsburg, A. Luckie, M. Mauget-Faysse, G. Coscas, N. E. Gross, and L. A. Yannuzzi Choroidal Infarction Following Photodynamic Therapy With Verteporfin Arch Ophthalmol, August 1, 2005; 123(8): 1149 - 1153. [Full Text] [PDF]
|
|
|
|
|
|
M. Varano, V. Parisi, M. Tedeschi, M. Sciamanna, G. Gallinaro, N. Capaldo, S. Catalano, and A. Pascarella Macular Function after PDT in Myopic Maculopathy: Psychophysical and Electrophysiological Evaluation Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1453 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Visudyne in Minimally Classic Choroidal Neovascula Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration: 2-Year Results of a Randomized Clinical Trial Arch Ophthalmol, April 1, 2005; 123(4): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Armbrecht, P A Aspinall, and B Dhillon A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration Br. J. Ophthalmol., October 1, 2004; 88(10): 1270 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Gelisken, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, and K U Bartz-Schmidt Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy Br. J. Ophthalmol., February 1, 2004; 88(2): 207 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W-M Chan, D S C Lam, T Y Y Lai, B S M Tam, D T L Liu, and C K M Chan Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level Br. J. Ophthalmol., December 1, 2003; 87(12): 1453 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G. O. H. Naumann Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4473 - 4480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Michels and U. Schmidt-Erfurth Sequence of Early Vascular Events after Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2147 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schmidt-Erfurth, H. Laqua, U. Schlotzer-Schrehard, A. Viestenz, and G. O. H. Naumann Histopathological Changes Following Photodynamic Therapy in Human Eyes Arch Ophthalmol, June 1, 2002; 120(6): 835 - 844. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
